echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > Lilly Abesili tablets officially approved for sale: domestic 2nd CDK4/6 inhibitors...

    Lilly Abesili tablets officially approved for sale: domestic 2nd CDK4/6 inhibitors...

    • Last Update: 2021-03-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Content Source: Pharmaceutical Rubik's Cube Info December 31, Lilly breast cancer new drug Abemaciclib in the domestic listing application (acceptance number: JXHS1900144, JXHS1900145, JXHS1900146) was approved by NMPA, becoming the second domestic listing after Cypressili 2 CDK4/6 inhibitors.
    Abesili's comedies are used in association with aromatase inhibitors as hormone-positive (HR), HER2-negative localized late-stage or metastatic post-menovascular female breast cancer patients with initial endocrine therapy, or in patients with advanced or metastatic HR plus, HER2-female breast cancer.
    's approval was based on a Phase III clinical study code-named MONARCH plus in women with post menopaus advanced breast cancer in China, with Queue A joining 306 patients with advanced stage breast cancer who had not previously received systematic treatment for initial endocrine therapy with Abesili or placebo combined nonsteroidal aromatase inhibitors.
    group B was treated with 157 patients who progressed after initial endocrine therapy, respectively, with Abesili or placebo combined fluorovis.
    results showed that in queue A, the median non-progressive survival time of patients in the Abesili combined nonsteroidal aromatase inhibitor group was longer than that of the placebo combined nonsteroidal aromatase inhibitor group (immature vs. 14.7 months, HR:0.499, p , 0.0001).
    the progression-free survival time of the Abesili group in queue B was also significantly different from that of the placebo group (11.5 vs. 5.6 months, HR:0.376; p < 0.0001))。
    Abersili combined with nonsteroidal aromatase inhibitors or fluvis groups is well-resistant and the safety data are consistent with Abesili's previous findings.
    , the Phase III clinical study, codenauly named MONARCH3, included 493 patients with post-menopathic hormone-positive HER2-negative progressive breast cancer without systematic treatment.
    results showed that the median non-progressive survival time of patients in the Abesili combined nonsteroidal aromatase inhibitor group was longer than that of the placebo combined nonsteroidal aromatase inhibitor group (28.18 vs 14.76 months, HR=0.540, P=0.000002).
    Phase III clinical study codenate MONKARCH2 included 669 patients with hormone-positive HER2-negative progression stage breast cancer who had previously received progression in endocrine therapy.
    results showed that the medium progression-free survival time of patients in the Abesili Combined Fluvis group was longer than that of the fluvis group monodride group (16.4 vs. 9.3 months, HR=0.553, P< (0.001), the total survival time of the middle is also longer than that of the fluorovis group single drug group (46.7 vs. 37.3 months, HR s 0.757, P s 0.0137).
    first approved by the FDA in September 2017 and then approved in Japan and the European Union, with global sales of $580 million in 2019.
    : The medical Rubik's Cube Next Pharma Abesili has also been developed by Lilly to treat non-small cell lung cancer, pancreatic cancer, prostate cancer and other adaptation certificates.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.